FDA will not regulate 'low-risk' healthcare technologies, apps

Cara Livernois | | Health Exec | Cybersecurity

Users of Fitbits and Weight Watchers can breathe a sigh of relief after the FDA announced its guidance stating that it would not be regulating low-risk products like mobile health and fitness apps.

The guidance comes into place as our technologies are evolving constantly, and mobile and apps are one of the most to advance thanks to new technology. The FDA not regulating these low-risk products gives them more room to grow and use innovation to get people more active and involved in their own health.

“I’m glad to see that the FDA recognizes this and has no current plans to put unnecessary government red tape between people hoping to use a Fitbit to help them get moving or a Weight Watchers application to monitor their diet,” stated Senate health committee Chairman Lamar Alexander.

The FDA will continue to regulate products that are invasive or implanted but this step out of the realm of wearable technology opens the doors for developers to let their imagination run wild.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Hackers were inside an Iowa hospital’s network for two weeks
Microsoft: Ransomware hit nearly 400 healthcare entities this year—a 300% rise since 2015
Feds make it official: Change data breach was the largest in healthcare history, impacting 100M
CMS contractor takes $1.2M loss after data breach, DOJ lawsuit
Boston Children's physician group suffers data breach
Homeland Security warns healthcare organizations of hackers using 'password spraying' tactic

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup